



MAVDA Newsletter

12 January 2024 | Issue 4



As we approach the second anniversary milestone of MAVDA, let us take a moment to reflect on the significant progress achieved as a consortium. We eagerly anticipate insights from our esteemed project/core leaders, as well as our DRP and MRP investigators, regarding the latest developments as we prepare to present at the 2nd MAVDA Annual Scientific Retreat.

It is imperative that we highlight the most promising lead and/or optimized lead compounds during this presentation and articulate the next steps toward IND enabling stages. The recognition and achievement of these milestones serves as a tangible indicator of programmatic success, thereby reinforcing the importance of our collective efforts.

Maintaining this momentum is critical, and we must remain steadfast in our commitment to advancing preclinical antiviral drug candidates. Looking ahead, expediting our programs toward IND enabling stages not only ensures the potential for continued success within MAVDA but also fortifies our position to secure future funding and support beyond the consortium.

We eagerly anticipate a highly successful 2nd Annual Retreat, where collaborative discussions and strategic planning will further contribute to the ongoing success of MAVDA.



IMPORTANT MEETING DATES

January 25-26, 2024 | 8am - 4pm | Annual Scientific Retreat (In-person)
CDI, Nutley, NJ

3 April, 2024 | 2-6pm |
NIH-NIAID Reverse site visit (Virtual)
<PLEASE NOTE CHANGE IN DATE>



MAVDA retreat deadlines

15 January 2024 - Written reports for SAB.

19 January 2024 - For poster presenters (Core leaders and MRP investigators). Final poster due for printing.

24 January 2024 - Final PPT (Project leaders and DRP investigators)



Annual report for NIH RPPR reporting

1 March, 2024 - Send RPPR forms documents to CDI(Madhu). Remind your administrators.

24 April, 2024 - Submission of Full RPPR to to NIH-NIAID (by CDI)